Ophthalmology – Sjögren’s Syndrome

What the Disease Represents

Sjögren’s syndrome, increasingly referred to as Sjögren disease, is a chronic systemic autoimmune disorder characterized by lymphocytic inflammation of the exocrine glands, particularly the:

• Lacrimal glands
• Salivary glands

The classic clinical combination is:

Aqueous-deficient dry eye + xerostomia

However, Sjögren disease is not simply a dry-eye disorder. It can affect multiple organ systems, including:

• Lungs
• Kidneys
• Peripheral and central nervous systems
• Skin
• Blood vessels
• Liver
• Musculoskeletal system
• Hematologic system

A major long-term concern is an increased risk of:

B-cell non-Hodgkin lymphoma.

Who Is Most Commonly Affected

Sjögren disease occurs predominantly in:

• Women
• Usually during middle age

Women are affected far more often than men.

However, the disease can occur:

• In younger adults
• In older adults
• Rarely in children

Why the Glands Stop Functioning

The precise initiating cause is unknown.

The current model involves:

Genetic susceptibility + environmental or infectious trigger → autoimmune activation → B- and T-cell-mediated glandular inflammation

This leads to:

• Lymphocytic infiltration
• Acinar cell dysfunction
• Progressive exocrine gland damage
• Reduced tear and saliva production

The Main Ocular Mechanism

The principal ophthalmic manifestation is:

Severe aqueous-deficient dry eye

because inflammation reduces lacrimal gland secretion.

This causes:

• Tear-film hyperosmolarity
• Ocular surface inflammation
• Epithelial damage
• Neuropathic symptoms in selected patients

Primary and Associated Disease

Historically, Sjögren was divided into:

• Primary Sjögren syndrome — occurring independently
• Secondary Sjögren syndrome — occurring with another autoimmune disease

The term “secondary Sjögren” is now used less consistently because Sjögren disease can coexist with another autoimmune condition without being merely secondary to it.

Common accompanying autoimmune disorders include:

• Rheumatoid arthritis
• Systemic lupus erythematosus
• Systemic sclerosis
• Autoimmune thyroid disease
• Mixed connective tissue disease
• Autoimmune liver disease

Typical Eye Complaints

Patients may report:

• Burning
• Grittiness
• Foreign-body sensation
• Stinging
• Intermittent blurred vision
• Photophobia
• Excessive reflex tearing
• Difficulty wearing contact lenses
• Frequent need for artificial tears

Symptoms may worsen with:

• Reading
• Computer use
• Air conditioning
• Wind
• Low humidity

Typical Oral Complaints

Ask specifically about:

• Persistent dry mouth
• Difficulty swallowing dry food
• Need to sip water while eating
• Frequent dental caries
• Oral candidiasis
• Difficulty speaking for long periods
• Recurrent salivary gland swelling

Parotid enlargement may occur intermittently.

Systemic Clues That Support the Diagnosis

Other symptoms may include:

• Severe fatigue
• Arthralgia
• Arthritis
• Raynaud phenomenon
• Peripheral neuropathy
• Purpura or vasculitic lesions
• Chronic cough or dyspnea
• Renal abnormalities
• Recurrent parotid swelling

These can help distinguish Sjögren disease from uncomplicated age-related dry eye.

Eyelid and Tear-Film Assessment

Examine for coexisting:

• Meibomian gland dysfunction
• Blepharitis
• Incomplete blink
• Lid malposition

Sjögren patients may have both:

Aqueous-deficient and evaporative dry eye

so treating only one mechanism may leave significant symptoms.

Tear Meniscus Findings

The tear meniscus is often:

• Reduced
• Thin
• Difficult to visualize

This reflects decreased aqueous production.

Tear Break-Up Time

Tear-film break-up time may be shortened because of:

• Tear instability
• Mucin abnormalities
• Coexisting MGD

However, tear break-up time alone is:

Not specific for Sjögren disease.

Ocular Surface Staining

Corneal and conjunctival epithelial damage can be demonstrated with:

• Fluorescein
• Lissamine green

Lissamine green is generally better tolerated than older rose bengal staining.

Typical staining is often most prominent in the:

• Interpalpebral conjunctiva
• Inferior cornea
• Nasal and temporal bulbar conjunctiva

Schirmer Testing

The Schirmer I test without anesthesia measures:

• Basal tear secretion
• Reflex tearing

A result of:

≤5 mm wetting in 5 minutes

supports significant aqueous tear deficiency and contributes to current classification criteria.

Why Schirmer Is Not Enough by Itself

A low Schirmer result can occur in:

• Other forms of aqueous-deficient dry eye
• Older age
• Medication-related dry eye

Therefore:

Sjögren disease cannot be diagnosed by Schirmer testing alone.

Modern Classification Framework

The commonly used 2016 ACR/EULAR classification criteria use a weighted scoring system.

Important components include:

• Anti-Ro/SSA positivity
• Labial salivary gland biopsy showing focal lymphocytic sialadenitis with focus score ≥1
• Ocular surface staining
• Schirmer ≤5 mm/5 min
• Reduced unstimulated whole salivary flow

A total score of:

≥4

in an appropriate patient supports classification as Sjögren disease.

The Most Important Autoantibody

The key serologic marker is:

Anti-Ro/SSA

It carries substantially more diagnostic weight than many other autoimmune markers.

Role of Anti-La/SSB

Anti-La/SSB may occur with Sjögren disease, but:

Anti-SSB positivity alone is not part of the current ACR/EULAR classification criteria.

It is therefore supportive rather than independently diagnostic.

ANA and Rheumatoid Factor

Patients commonly have:

• Positive ANA
• Positive rheumatoid factor

but these tests are:

Nonspecific

and are not sufficient to establish the diagnosis.

Salivary Gland Biopsy

A minor labial salivary gland biopsy may demonstrate:

Focal lymphocytic sialadenitis

with clusters of lymphocytes surrounding ducts.

A focus score of:

≥1 focus per 4 mm²

is an important diagnostic criterion.

When Biopsy Is Especially Useful

Minor salivary gland biopsy is particularly helpful when:

• Anti-SSA is negative
• Clinical suspicion remains high
• Classification is uncertain

It is generally preferred to lacrimal gland biopsy because it is:

• Less invasive
• More standardized

Salivary Gland Ultrasound

Ultrasound of the major salivary glands is increasingly used to identify:

• Heterogeneous echotexture
• Hypoechoic areas
• Glandular structural damage

It is useful as an adjunct but is not yet universally incorporated into formal classification criteria.

Tests No Longer Central to Routine Diagnosis

Older approaches relied more heavily on:

• Salivary scintigraphy
• Parotid sialography
• Rose bengal scoring

These may still be useful in selected settings but are less central than:

• Anti-SSA
• Salivary gland biopsy
• Ocular staining
• Schirmer testing
• Salivary flow measurement

Dry Eye Conditions That Can Mimic Sjögren

Important alternatives include:

• Age-related dry eye
• Medication-induced dry eye
• Meibomian gland dysfunction
• Blepharitis
• Exposure keratopathy
• Thyroid eye disease
• Vitamin A deficiency
• Neurotrophic keratopathy
• Graft-versus-host disease

Causes of Dry Mouth That Can Mimic Sjögren

These include:

• Anticholinergic medications
• Antidepressants
• Antihistamines
• Dehydration
• Mouth breathing
• Head and neck radiation
• Diabetes
• Salivary gland disease

Medication review is therefore essential.

Infiltrative Conditions to Exclude

Dry eye and lacrimal gland abnormalities can also occur with:

• Sarcoidosis
• IgG4-related disease
• Amyloidosis
• Lymphoma

These become particularly important when there is:

• Marked gland enlargement
• Atypical orbital findings
• Unusual systemic features

First Step in Ocular Treatment

Management usually begins with:

Preservative-free artificial tears

especially when drops are needed frequently.

Additional lubrication may include:

• Gels
• Ointments at night

Why Preservative-Free Drops Matter

Frequent exposure to preservatives, especially benzalkonium chloride, can worsen:

• Surface toxicity
• Epithelial inflammation
• Dry-eye symptoms

Patients requiring drops more than a few times daily generally benefit from:

Preservative-free formulations.

Controlling Ocular Surface Inflammation

Because Sjögren dry eye is inflammatory, lubrication alone may be insufficient.

Long-term anti-inflammatory therapy may include:

• Topical cyclosporine
• Lifitegrast
• Other approved immunomodulatory dry-eye agents depending on availability

Topical Cyclosporine

Cyclosporine can:

• Reduce T-cell-mediated ocular surface inflammation
• Improve tear production in some patients
• Improve staining over time

Patients should be counseled that:

• Burning on instillation can occur
• Improvement may require several weeks to months

Short Courses of Topical Steroid

A topical corticosteroid may be useful for:

• Moderate-to-severe inflammatory flares
• Rapid control while slower immunomodulators begin working

Long-term unsupervised steroid use should be avoided because of:

• IOP elevation
• Glaucoma
• Cataract
• Infection

Managing Meibomian Gland Dysfunction

If MGD coexists, treatment may include:

• Warm compresses
• Lid hygiene
• Meibomian gland expression
• Appropriate topical therapy
• Selected oral tetracycline-class therapy for rosacea/MGD

Treating MGD can significantly improve:

Tear-film stability even when aqueous deficiency persists.

Filamentary Keratitis

Severe aqueous deficiency may produce:

Filamentary keratitis

Symptoms include:

• Foreign-body sensation
• Sharp pain
• Photophobia

Management may include:

• Intensive lubrication
• Mechanical filament removal
• Hypertonic or mucolytic therapy
• N-acetylcysteine in selected cases
• Bandage or scleral lens in refractory cases

Autologous Serum Tears

For severe ocular surface disease, autologous serum tears can provide:

• Growth factors
• Vitamin A
• Epitheliotrophic components

They may help with:

• Persistent epithelial disease
• Severe staining
• Refractory symptoms

Platelet-Based Eye Drops

Selected centers also use:

• Platelet-rich plasma
• Plasma rich in growth factors

for severe refractory ocular surface disease.

Availability and protocols vary.

Punctal Occlusion

Punctal plugs or cautery can reduce tear drainage.

They may be useful when there is significant:

Aqueous deficiency

However, significant ocular surface inflammation should ideally be controlled first because occlusion may retain:

Inflammatory tear-film mediators.

Scleral Lenses

Severe Sjögren dry eye may benefit greatly from:

Scleral contact lenses

which create a fluid reservoir over the cornea.

They can:

• Protect the epithelium
• Improve comfort
• Improve vision
• Reduce exposure

They are particularly useful in advanced ocular surface disease.

Moisture Conservation

Helpful environmental measures include:

• Humidifiers
• Avoiding direct fan or air-conditioning airflow
• Wraparound moisture-chamber glasses
• Frequent blinking during screen use

These measures improve comfort but do not modify the systemic autoimmune disease.

Evidence for Omega-3 Supplements

Older recommendations commonly advised:

• Fish oil
• Flaxseed oil

However, modern evidence for omega-3 supplementation in dry eye is:

Mixed and not sufficiently consistent to regard it as a standard Sjögren dry-eye treatment.

A normal balanced diet remains appropriate.

Severe Corneal Disease

Advanced ocular surface failure may cause:

• Persistent epithelial defect
• Sterile corneal melt
• Microbial keratitis
• Corneal scarring

These situations require:

Urgent ophthalmic treatment.

When Tarsorrhaphy Is Needed

Temporary or permanent tarsorrhaphy may be considered in severe cases with:

• Persistent epithelial breakdown
• Exposure
• Corneal thinning
• Failure of intensive medical therapy

This is usually reserved for:

Advanced ocular surface disease.

Managing Dry Mouth

Systemic measures may include:

• Frequent water intake
• Sugar-free gum
• Saliva substitutes
• Intensive dental care

Muscarinic agonists can stimulate salivary secretion.

Pilocarpine and Cevimeline

Oral secretagogues include:

• Pilocarpine
• Cevimeline

They may improve:

• Xerostomia
• Occasionally ocular dryness

Potential adverse effects include:

• Sweating
• Flushing
• Urinary frequency
• Gastrointestinal symptoms

They are contraindicated or used cautiously in selected cardiopulmonary conditions.

Why Medication Review Matters

Drugs with anticholinergic effects can worsen both:

• Dry eye
• Dry mouth

Examples include some:

• Antihistamines
• Antidepressants
• Bladder medications
• Antipsychotics

Medication changes should be coordinated with the prescribing clinician.

Systemic Immunomodulatory Therapy

Systemic therapy is determined by the:

Extraglandular manifestations

rather than dry eye alone.

Agents may include:

• Hydroxychloroquine
• Methotrexate
• Mycophenolate
• Azathioprine
• Corticosteroids
• Rituximab or other biologics in selected severe disease

Management is usually coordinated by:

Rheumatology.

Hydroxychloroquine and the Eye

Patients taking long-term hydroxychloroquine require:

Retinal toxicity screening

according to current dosing and screening recommendations.

Hydroxychloroquine is not primarily a treatment for ocular surface dryness.

Systemic Problems Worth Screening For

Sjögren disease may involve:

• Interstitial lung disease
• Peripheral neuropathy
• Renal tubular acidosis
• Glomerular disease
• Vasculitis
• Autoimmune liver disease
• Thyroid disease
• Cytopenias

Persistent systemic symptoms warrant multidisciplinary evaluation.

The Lymphoma Connection

Patients with Sjögren disease have a substantially increased risk of:

B-cell non-Hodgkin lymphoma, especially mucosa-associated lymphoid tissue lymphoma.

The absolute lifetime risk is commonly estimated at roughly:

5–10%, depending on the population and risk profile.

Features That Raise Lymphoma Concern

Concerning features include:

• Persistent major salivary gland enlargement
• Lymphadenopathy
• Splenomegaly
• Palpable purpura
• Cryoglobulinemia
• Low complement, particularly C4
• Monoclonal gammopathy
• Unexplained weight loss or fever

These warrant prompt systemic assessment.

Pregnancy and Anti-Ro/SSA Antibodies

Maternal anti-Ro/SSA antibodies can cross the placenta and cause:

Neonatal lupus

The most important complication is:

Congenital heart block

The risk in a first anti-Ro-positive pregnancy is relatively low, but recurrence risk is much higher after a previously affected pregnancy.

Pregnancy Monitoring

Anti-Ro/SSA-positive pregnant patients should receive:

• Maternal-fetal medicine assessment
• Appropriate fetal cardiac surveillance

Management should be individualized according to:

• Antibody status
• Prior pregnancy history
• Rheumatologic disease activity

Sjögren Disease in Children

Pediatric Sjögren disease is uncommon.

Children may present differently from adults, particularly with:

Recurrent parotid gland swelling

before developing prominent:

• Dry eye
• Dry mouth

Therefore classic adult sicca symptoms may be absent early.

When Ophthalmology Should Suspect Sjögren Disease

Consider systemic evaluation when dry eye is:

• Severe
• Clearly aqueous deficient
• Disproportionate to age
• Refractory to routine treatment
• Associated with dry mouth
• Associated with systemic autoimmune symptoms

Ophthalmologists may be the first clinicians to recognize the disease.

When Rheumatology Referral Is Appropriate

Referral is appropriate when there is:

• Strong Sjögren suspicion
• Positive anti-SSA
• Significant xerostomia
• Arthritis
• Vasculitic symptoms
• Neuropathy
• Pulmonary or renal disease

Diagnosis and long-term systemic management are best handled:

Multidisciplinarily.

Follow-Up Strategy

Ophthalmic follow-up depends on severity rather than a fixed schedule for every patient.

Monitor:

• Visual acuity
• Corneal staining
• Conjunctival staining
• Tear production
• Tear stability
• MGD
• Corneal integrity
• IOP when corticosteroids are used

Severe disease requires more frequent review.

Expected Ocular Course

Sjögren dry eye is:

Chronic

but symptoms and surface damage can often be substantially improved with:

• Lubrication
• Anti-inflammatory therapy
• Tear conservation
• Serum tears
• Scleral lenses

The disease itself is not currently curable.

Factors That Threaten Vision

Most patients retain good vision, but serious complications may occur with severe ocular surface disease, including:

• Persistent epithelial defects
• Infectious keratitis
• Sterile corneal melt
• Corneal ulceration
• Scarring
• Rare perforation

Rapid worsening of pain, redness, or vision requires urgent examination.

High-Yield Takeaways

• Sjögren disease is a systemic autoimmune disorder causing lymphocytic injury to the lacrimal and salivary glands, producing aqueous-deficient dry eye and xerostomia.
• Severe or refractory dry eye associated with dry mouth, fatigue, arthritis, recurrent parotid swelling, or systemic autoimmune symptoms should raise suspicion for Sjögren disease.
• Ocular surface examination commonly shows reduced tear meniscus, corneal/conjunctival staining, and low Schirmer values.
• Schirmer ≤5 mm in 5 minutes contributes to modern classification but is not diagnostic by itself.
• Current ACR/EULAR classification emphasizes anti-Ro/SSA antibodies, minor salivary gland biopsy, ocular staining, Schirmer testing, and reduced salivary flow.
• Anti-SSA is the key serologic marker; isolated anti-SSB positivity is no longer sufficient for classification.
• ANA and rheumatoid factor are common but nonspecific.
• First-line ocular management includes preservative-free lubrication and treatment of coexisting MGD.
• Chronic inflammatory dry eye often benefits from topical cyclosporine, lifitegrast, or another approved anti-inflammatory dry-eye therapy.
• Short courses of topical corticosteroid can control flares but require monitoring for IOP elevation and cataract.
• Severe disease may require autologous serum tears, punctal occlusion, scleral lenses, or occasionally tarsorrhaphy.
• Punctal occlusion is often best performed after significant surface inflammation has been controlled.
• Omega-3 supplementation has inconsistent evidence and should not be considered an established Sjögren-specific treatment.
• The major corneal threats are epithelial breakdown, sterile melt, microbial keratitis, scarring, and rarely perforation.
• Sjögren disease is systemic: pulmonary, renal, neurologic, vascular, and hematologic involvement may occur.
• Patients have an increased risk of B-cell lymphoma, particularly with persistent gland enlargement, cryoglobulinemia, low C4, purpura, or lymphadenopathy.
• Anti-Ro/SSA-positive pregnancy carries a risk of neonatal lupus and congenital heart block, warranting maternal-fetal medicine involvement.
• Pediatric disease may initially present with recurrent parotitis rather than classic sicca symptoms.
• Long-term care is best coordinated between ophthalmology, rheumatology, dentistry/oral medicine, and other specialists according to systemic involvement.

Who Is Most Commonly Affected Sjögren disease occurs predominantly in:  Women Usually during middle age  Women are affected far more often than men. However, the disease can occur:  In younger adults In older adults Rarely in children

Why the Glands Stop Functioning The precise initiating cause is unknown. The current model involves: Genetic susceptibility + environmental or infectious trigger → autoimmune activation → B- and T-cell-mediated glandular inflammation This leads to:  Lymphocytic infiltration Acinar cell dysfunction Progressive exocrine gland damage Reduced tear and saliva production

The Main Ocular Mechanism The principal ophthalmic manifestation is: Severe aqueous-deficient dry eye because inflammation reduces lacrimal gland secretion. This causes:  Tear-film hyperosmolarity Ocular surface inflammation Epithelial damage Neuropathic symptoms in selected patients

Primary and Associated Disease Historically, Sjögren was divided into:  Primary Sjögren syndrome — occurring independently Secondary Sjögren syndrome — occurring with another autoimmune disease  The term “secondary Sjögren” is now used less consistently because Sjögren disease can coexist with another autoimmune condition without being merely secondary to it. Common accompanying autoimmune disorders include:  Rheumatoid arthritis Systemic lupus erythematosus Systemic sclerosis Autoimmune thyroid disease Mixed connective tissue disease Autoimmune liver disease

Typical Eye Complaints Patients may report:  Burning Grittiness Foreign-body sensation Stinging Intermittent blurred vision Photophobia Excessive reflex tearing Difficulty wearing contact lenses Frequent need for artificial tears  Symptoms may worsen with:  Reading Computer use Air conditioning Wind Low humidity

Typical Oral Complaints Ask specifically about:  Persistent dry mouth Difficulty swallowing dry food Need to sip water while eating Frequent dental caries Oral candidiasis Difficulty speaking for long periods Recurrent salivary gland swelling  Parotid enlargement may occur intermittently.

Systemic Clues That Support the Diagnosis Other symptoms may include:  Severe fatigue Arthralgia Arthritis Raynaud phenomenon Peripheral neuropathy Purpura or vasculitic lesions Chronic cough or dyspnea Renal abnormalities Recurrent parotid swelling  These can help distinguish Sjögren disease from uncomplicated age-related dry eye.

Eyelid and Tear-Film Assessment Examine for coexisting:  Meibomian gland dysfunction Blepharitis Incomplete blink Lid malposition  Sjögren patients may have both: Aqueous-deficient and evaporative dry eye so treating only one mechanism may leave significant symptoms.

Tear Meniscus Findings The tear meniscus is often:  Reduced Thin Difficult to visualize  This reflects decreased aqueous production.

Tear Break-Up Time Tear-film break-up time may be shortened because of:  Tear instability Mucin abnormalities Coexisting MGD  However, tear break-up time alone is: Not specific for Sjögren disease.

Ocular Surface Staining Corneal and conjunctival epithelial damage can be demonstrated with:  Fluorescein Lissamine green  Lissamine green is generally better tolerated than older rose bengal staining. Typical staining is often most prominent in the:  Interpalpebral conjunctiva Inferior cornea Nasal and temporal bulbar conjunctiva

Schirmer Testing The Schirmer I test without anesthesia measures:  Basal tear secretion Reflex tearing  A result of: ≤5 mm wetting in 5 minutes supports significant aqueous tear deficiency and contributes to current classification criteria.

Why Schirmer Is Not Enough by Itself A low Schirmer result can occur in:  Other forms of aqueous-deficient dry eye Older age Medication-related dry eye  Therefore: Sjögren disease cannot be diagnosed by Schirmer testing alone.

Modern Classification Framework The commonly used 2016 ACR/EULAR classification criteria use a weighted scoring system. Important components include:  Anti-Ro/SSA positivity Labial salivary gland biopsy showing focal lymphocytic sialadenitis with focus score ≥1 Ocular surface staining Schirmer ≤5 mm/5 min Reduced unstimulated whole salivary flow  A total score of: ≥4 in an appropriate patient supports classification as Sjögren disease.

The Most Important Autoantibody The key serologic marker is: Anti-Ro/SSA It carries substantially more diagnostic weight than many other autoimmune markers.

Role of Anti-La/SSB Anti-La/SSB may occur with Sjögren disease, but: Anti-SSB positivity alone is not part of the current ACR/EULAR classification criteria. It is therefore supportive rather than independently diagnostic.

ANA and Rheumatoid Factor Patients commonly have:  Positive ANA Positive rheumatoid factor  but these tests are: Nonspecific and are not sufficient to establish the diagnosis.

Salivary Gland Biopsy A minor labial salivary gland biopsy may demonstrate: Focal lymphocytic sialadenitis with clusters of lymphocytes surrounding ducts. A focus score of: ≥1 focus per 4 mm² is an important diagnostic criterion.

When Biopsy Is Especially Useful Minor salivary gland biopsy is particularly helpful when:  Anti-SSA is negative Clinical suspicion remains high Classification is uncertain  It is generally preferred to lacrimal gland biopsy because it is:  Less invasive More standardized

Salivary Gland Ultrasound Ultrasound of the major salivary glands is increasingly used to identify:  Heterogeneous echotexture Hypoechoic areas Glandular structural damage  It is useful as an adjunct but is not yet universally incorporated into formal classification criteria.

Tests No Longer Central to Routine Diagnosis Older approaches relied more heavily on:  Salivary scintigraphy Parotid sialography Rose bengal scoring  These may still be useful in selected settings but are less central than:  Anti-SSA Salivary gland biopsy Ocular staining Schirmer testing Salivary flow measurement

Dry Eye Conditions That Can Mimic Sjögren Important alternatives include:  Age-related dry eye Medication-induced dry eye Meibomian gland dysfunction Blepharitis Exposure keratopathy Thyroid eye disease Vitamin A deficiency Neurotrophic keratopathy Graft-versus-host disease

Causes of Dry Mouth That Can Mimic Sjögren These include:  Anticholinergic medications Antidepressants Antihistamines Dehydration Mouth breathing Head and neck radiation Diabetes Salivary gland disease  Medication review is therefore essential.

Infiltrative Conditions to Exclude Dry eye and lacrimal gland abnormalities can also occur with:  Sarcoidosis IgG4-related disease Amyloidosis Lymphoma  These become particularly important when there is:  Marked gland enlargement Atypical orbital findings Unusual systemic features

First Step in Ocular Treatment Management usually begins with: Preservative-free artificial tears especially when drops are needed frequently. Additional lubrication may include:  Gels Ointments at night

Why Preservative-Free Drops Matter Frequent exposure to preservatives, especially benzalkonium chloride, can worsen:  Surface toxicity Epithelial inflammation Dry-eye symptoms  Patients requiring drops more than a few times daily generally benefit from: Preservative-free formulations.

Controlling Ocular Surface Inflammation Because Sjögren dry eye is inflammatory, lubrication alone may be insufficient. Long-term anti-inflammatory therapy may include:  Topical cyclosporine Lifitegrast Other approved immunomodulatory dry-eye agents depending on availability

Topical Cyclosporine Cyclosporine can:  Reduce T-cell-mediated ocular surface inflammation Improve tear production in some patients Improve staining over time  Patients should be counseled that:  Burning on instillation can occur Improvement may require several weeks to months

Short Courses of Topical Steroid A topical corticosteroid may be useful for:  Moderate-to-severe inflammatory flares Rapid control while slower immunomodulators begin working  Long-term unsupervised steroid use should be avoided because of:  IOP elevation Glaucoma Cataract Infection

Managing Meibomian Gland Dysfunction If MGD coexists, treatment may include:  Warm compresses Lid hygiene Meibomian gland expression Appropriate topical therapy Selected oral tetracycline-class therapy for rosacea/MGD  Treating MGD can significantly improve: Tear-film stability even when aqueous deficiency persists.

Filamentary Keratitis Severe aqueous deficiency may produce: Filamentary keratitis Symptoms include:  Foreign-body sensation Sharp pain Photophobia  Management may include:  Intensive lubrication Mechanical filament removal Hypertonic or mucolytic therapy N-acetylcysteine in selected cases Bandage or scleral lens in refractory cases

Autologous Serum Tears For severe ocular surface disease, autologous serum tears can provide:  Growth factors Vitamin A Epitheliotrophic components  They may help with:  Persistent epithelial disease Severe staining Refractory symptoms

Platelet-Based Eye Drops Selected centers also use:  Platelet-rich plasma Plasma rich in growth factors  for severe refractory ocular surface disease. Availability and protocols vary.

Punctal Occlusion Punctal plugs or cautery can reduce tear drainage. They may be useful when there is significant: Aqueous deficiency However, significant ocular surface inflammation should ideally be controlled first because occlusion may retain: Inflammatory tear-film mediators.

Scleral Lenses Severe Sjögren dry eye may benefit greatly from: Scleral contact lenses which create a fluid reservoir over the cornea. They can:  Protect the epithelium Improve comfort Improve vision Reduce exposure  They are particularly useful in advanced ocular surface disease.

Moisture Conservation Helpful environmental measures include:  Humidifiers Avoiding direct fan or air-conditioning airflow Wraparound moisture-chamber glasses Frequent blinking during screen use  These measures improve comfort but do not modify the systemic autoimmune disease.

Evidence for Omega-3 Supplements Older recommendations commonly advised:  Fish oil Flaxseed oil  However, modern evidence for omega-3 supplementation in dry eye is: Mixed and not sufficiently consistent to regard it as a standard Sjögren dry-eye treatment. A normal balanced diet remains appropriate.

Severe Corneal Disease Advanced ocular surface failure may cause:  Persistent epithelial defect Sterile corneal melt Microbial keratitis Corneal scarring  These situations require: Urgent ophthalmic treatment.

When Tarsorrhaphy Is Needed Temporary or permanent tarsorrhaphy may be considered in severe cases with:  Persistent epithelial breakdown Exposure Corneal thinning Failure of intensive medical therapy  This is usually reserved for: Advanced ocular surface disease.

Managing Dry Mouth Systemic measures may include:  Frequent water intake Sugar-free gum Saliva substitutes Intensive dental care  Muscarinic agonists can stimulate salivary secretion.

Pilocarpine and Cevimeline Oral secretagogues include:  Pilocarpine Cevimeline  They may improve:  Xerostomia Occasionally ocular dryness  Potential adverse effects include:  Sweating Flushing Urinary frequency Gastrointestinal symptoms  They are contraindicated or used cautiously in selected cardiopulmonary conditions.

Why Medication Review Matters Drugs with anticholinergic effects can worsen both:  Dry eye Dry mouth  Examples include some:  Antihistamines Antidepressants Bladder medications Antipsychotics  Medication changes should be coordinated with the prescribing clinician.

Systemic Immunomodulatory Therapy Systemic therapy is determined by the: Extraglandular manifestations rather than dry eye alone. Agents may include:  Hydroxychloroquine Methotrexate Mycophenolate Azathioprine Corticosteroids Rituximab or other biologics in selected severe disease  Management is usually coordinated by: Rheumatology.

Hydroxychloroquine and the Eye Patients taking long-term hydroxychloroquine require: Retinal toxicity screening according to current dosing and screening recommendations. Hydroxychloroquine is not primarily a treatment for ocular surface dryness.

Systemic Problems Worth Screening For Sjögren disease may involve:  Interstitial lung disease Peripheral neuropathy Renal tubular acidosis Glomerular disease Vasculitis Autoimmune liver disease Thyroid disease Cytopenias  Persistent systemic symptoms warrant multidisciplinary evaluation.

The Lymphoma Connection Patients with Sjögren disease have a substantially increased risk of: B-cell non-Hodgkin lymphoma, especially mucosa-associated lymphoid tissue lymphoma. The absolute lifetime risk is commonly estimated at roughly: 5–10%, depending on the population and risk profile.

Features That Raise Lymphoma Concern Concerning features include:  Persistent major salivary gland enlargement Lymphadenopathy Splenomegaly Palpable purpura Cryoglobulinemia Low complement, particularly C4 Monoclonal gammopathy Unexplained weight loss or fever  These warrant prompt systemic assessment.

Pregnancy and Anti-Ro/SSA Antibodies Maternal anti-Ro/SSA antibodies can cross the placenta and cause: Neonatal lupus The most important complication is: Congenital heart block The risk in a first anti-Ro-positive pregnancy is relatively low, but recurrence risk is much higher after a previously affected pregnancy.

Pregnancy Monitoring Anti-Ro/SSA-positive pregnant patients should receive:  Maternal-fetal medicine assessment Appropriate fetal cardiac surveillance  Management should be individualized according to:  Antibody status Prior pregnancy history Rheumatologic disease activity

Sjögren Disease in Children Pediatric Sjögren disease is uncommon. Children may present differently from adults, particularly with: Recurrent parotid gland swelling before developing prominent:  Dry eye Dry mouth  Therefore classic adult sicca symptoms may be absent early.

When Ophthalmology Should Suspect Sjögren Disease Consider systemic evaluation when dry eye is:  Severe Clearly aqueous deficient Disproportionate to age Refractory to routine treatment Associated with dry mouth Associated with systemic autoimmune symptoms  Ophthalmologists may be the first clinicians to recognize the disease.

When Rheumatology Referral Is Appropriate Referral is appropriate when there is:  Strong Sjögren suspicion Positive anti-SSA Significant xerostomia Arthritis Vasculitic symptoms Neuropathy Pulmonary or renal disease  Diagnosis and long-term systemic management are best handled: Multidisciplinarily.

Follow-Up Strategy Ophthalmic follow-up depends on severity rather than a fixed schedule for every patient. Monitor:  Visual acuity Corneal staining Conjunctival staining Tear production Tear stability MGD Corneal integrity IOP when corticosteroids are used  Severe disease requires more frequent review.

Expected Ocular Course Sjögren dry eye is: Chronic but symptoms and surface damage can often be substantially improved with:  Lubrication Anti-inflammatory therapy Tear conservation Serum tears Scleral lenses  The disease itself is not currently curable.

Factors That Threaten Vision Most patients retain good vision, but serious complications may occur with severe ocular surface disease, including:  Persistent epithelial defects Infectious keratitis Sterile corneal melt Corneal ulceration Scarring Rare perforation  Rapid worsening of pain, redness, or vision requires urgent examination.

High-Yield Takeaways  Sjögren disease is a systemic autoimmune disorder causing lymphocytic injury to the lacrimal and salivary glands, producing aqueous-deficient dry eye and xerostomia. Severe or refractory dry eye associated with dry mouth, fatigue, arthritis, recurrent parotid swelling, or systemic autoimmune symptoms should raise suspicion for Sjögren disease. Ocular surface examination commonly shows reduced tear meniscus, corneal/conjunctival staining, and low Schirmer values. Schirmer ≤5 mm in 5 minutes contributes to modern classification but is not diagnostic by itself. Current ACR/EULAR classification emphasizes anti-Ro/SSA antibodies, minor salivary gland biopsy, ocular staining, Schirmer testing, and reduced salivary flow. Anti-SSA is the key serologic marker; isolated anti-SSB positivity is no longer sufficient for classification. ANA and rheumatoid factor are common but nonspecific. First-line ocular management includes preservative-free lubrication and treatment of coexisting MGD. Chronic inflammatory dry eye often benefits from topical cyclosporine, lifitegrast, or another approved anti-inflammatory dry-eye therapy. Short courses of topical corticosteroid can control flares but require monitoring for IOP elevation and cataract. Severe disease may require autologous serum tears, punctal occlusion, scleral lenses, or occasionally tarsorrhaphy. Punctal occlusion is often best performed after significant surface inflammation has been controlled. Omega-3 supplementation has inconsistent evidence and should not be considered an established Sjögren-specific treatment. The major corneal threats are epithelial breakdown, sterile melt, microbial keratitis, scarring, and rarely perforation. Sjögren disease is systemic: pulmonary, renal, neurologic, vascular, and hematologic involvement may occur. Patients have an increased risk of B-cell lymphoma, particularly with persistent gland enlargement, cryoglobulinemia, low C4, purpura, or lymphadenopathy. Anti-Ro/SSA-positive pregnancy carries a risk of neonatal lupus and congenital heart block, warranting maternal-fetal medicine involvement. Pediatric disease may initially present with recurrent parotitis rather than classic sicca symptoms. Long-term care is best coordinated between ophthalmology, rheumatology, dentistry/oral medicine, and other specialists according to systemic involvement.